Nouveautés Loi 31 – Enfin! Mais comment faire mieux avec nos patients en santé respiratoire?
L’ajout récent des prises en charge pour l’asthme et la MPOC dans les actes de la Loi 31 est une opportunité intéressante et rentable d’améliorer la santé respiratoire des patients. Ce webinaire vous permettra de mettre à jour vos connaissances en santé respiratoire, d’obtenir des outils pratiques afin de réaliser ces actes dans vos pharmacies et d’apprivoiser leur facturation. Un événement à ne pas manquer!
Join Professor Omar Usmani and Dr. John Pritchard as they review the environmental impact of inhaled medications. Tune in to discover how to develop patient centric strategies to reduce the impact of inhalers on the climate.
This conversation will cover:
Climate change and carbon impact of pressurised Metered Dose Inhalers (pMDIs)
Join Dr. Douglas Mack and Dr. Mariam Hanna as they discuss the importance of asthma control in today’s world, as well as the shift to virtual appointments including tools and tips to optimize virtual asthma assessments. Please see a recording of the session below.
Join Isabelle LeClerc in this 30-minute webinar as she discusses the importance of airway clearance techniques and oscillating positive expiratory pressure (OPEP) devices, including during the COVID-19 pandemic. Please see a recording of the session below.
Joignez-vous à David Gourde, Inf. et CRE, pour une discussion sur comment vous pouvez aider vos patients à libérer leurs poumons avec un traitement non-pharmacologique.
Cette session a été établie en partenariat avec Alliance Pharma.
Votre conférencier : David Gourde, Inf. B. Sc. CRE Intervenant pivot-réseau en maladies pulmonaires chroniques
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
New information regarding the efficiency and effectiveness of different oscillating positive expiratory pressure devices was presented at CHEST 2017 in Toronto, Canada.
Valved holding chambers are widely prescribed to assist patients receiving inhaled medications by avoiding losses caused by imperfect coordination of inhalation and actuation and also to reduce oropharyngeal deposition.
Regardless of whether using a solution based formulation (like Qvar) or a suspension formulation (Flovent), the use of a valved holding chamber reduced the amount of medication deposited in the mouth (oropharynx) and increased the potential for lung delivery
This study can be used to help demonstrate the value of using a valved holding chamber for both solution and suspension formulated metered dose inhalers and for all patient populations, including adults
Presented at the British Thoracic Society December 2018.
Having a child with asthma can be stressful for parents, especially for financially strapped ones struggling to pay for an arsenal of puffers and pills for their child’s treatment. Because of this, those healthcare professionals who recommend spacer chambers may suggest one of many lower-cost versions that are available on the market today. But focusing only on cost may be putting a child’s health at risk.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
More consistent dose delivery was achieved with the breath actuated technology rather than breath enhanced. Delivering medication only when the patient inhales would result in more stable therapy if I:E ratio was to change with disease< progression or if the patient took breaks to talk during treatment.
Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.
In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.
By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.
Join Dr. Sacha Bhinder, HBSc, MD, FRCPC, for a review of inhaled delivery device products that are available in Canada, and how to foster customized care when choosing the most appropriate device for your patient.
The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
The influence of inhalation flow profile was significant for one of the DPIs.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
The FRI deposition profiles highlight that the MDI/ AeroChamber Plus* Flow Vu* VHC system delivered an appreciably greater percentage of drug to the lung region than either of the two DPIs.
The influence of inhalation flow profile was less with the MDI/VHC system and differed between the two DPIs.
